BACKGROUND: Herpesvirus entry mediator (HVEM) has been recently suggested to play certain roles in cancer biology. We examined HVEM expression in human colorectal cancer (CRC) to reveal its clinical importance. MATERIALS AND METHODS: Immunohistochemical staining was carried-out in normal epithelium, benign and malignant lesions. RESULTS: While intense HVEM expression was not observed in normal epithelium and hyperplastic polyps, 24% of adenoma and more than half of CRCs had high HVEM expression. In 234 CRCs, HVEM expression was significantly associated with tumor status and pathological stage. Patients with high HVEM expression had a significantly poorer prognosis than those with low expression. Importantly, HVEM status had an independent prognostic value in CRC. Furthermore, HVEM status was inversely corrected with the presence of tumor-infiltrating T-cells. CONCLUSION: HVEM may play a critical role in tumor progression and immune evasion, and may also be a novel prognostic marker and potential therapeutic target in human CRC. Copyright
BACKGROUND:Herpesvirus entry mediator (HVEM) has been recently suggested to play certain roles in cancer biology. We examined HVEM expression in humancolorectal cancer (CRC) to reveal its clinical importance. MATERIALS AND METHODS: Immunohistochemical staining was carried-out in normal epithelium, benign and malignant lesions. RESULTS: While intense HVEM expression was not observed in normal epithelium and hyperplastic polyps, 24% of adenoma and more than half of CRCs had high HVEM expression. In 234 CRCs, HVEM expression was significantly associated with tumor status and pathological stage. Patients with high HVEM expression had a significantly poorer prognosis than those with low expression. Importantly, HVEM status had an independent prognostic value in CRC. Furthermore, HVEM status was inversely corrected with the presence of tumor-infiltrating T-cells. CONCLUSION:HVEM may play a critical role in tumor progression and immune evasion, and may also be a novel prognostic marker and potential therapeutic target in human CRC. Copyright
Authors: Brian M Olson; Melissa Gamat; Joseph Seliski; Thomas Sawicki; Justin Jeffery; Leigh Ellis; Charles G Drake; Jamey Weichert; Douglas G McNeel Journal: Cancer Immunol Res Date: 2017-10-19 Impact factor: 11.151
Authors: Nausicaa Malissen; Nicolas Macagno; Samuel Granjeaud; Clémence Granier; Vincent Moutardier; Caroline Gaudy-Marqueste; Nadia Habel; Marion Mandavit; Bernard Guillot; Christine Pasero; Eric Tartour; Robert Ballotti; Jean-Jacques Grob; Daniel Olive Journal: Oncoimmunology Date: 2019-09-25 Impact factor: 8.110